This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Takebayashi, Y. Articles by Pommier, Y. Search for Related Content PubMed PubMed Citation Articles by Takebayashi, Y. Articles by Pommier, Y.

Ecteinascidin 743 Induces Protein-linked DNA Breaks in Human Colon Carcinoma HCT116 Cells and Is Cytotoxic Independently of Topoisomerase I Expression

Laboratory of Molecular Pharmacology, Division of Basic Sciences, National Cancer Institute, NIH, Bethesda, Maryland 20892-4255

Ecteinascidin 743 (Et743; NSC 648766) is a potent antitumor agent presently in clinical trials. Et743 selectively alkylates guanine N2 from the minor groove of duplex DNA and bends the DNA toward the major groove. This differentiates Et743 from other DNA-alkylating agents presently in the clinic. To date, the cellular effects of Et743 have not been elucidated. Recently, Et743 DNA adducts have been found to suppress gene expression selectively and to induce topoisomerase I (top1) cleavage complexes in vitro and top1-DNA complexes in cell culture. In the present study, we characterized the DNA damage and the cell cycle response induced by Et743 in human colon carcinoma HCT116 cells. Alkaline elution experiments demonstrated that micromolar concentrations of Et743 produced comparable frequencies of DNA-protein cross-links and DNA single-strand breaks. The single-strand breaks were protein-cross-linked and were not associated with detectable DNA double-strand breaks. By contrast with camptothecin, these lesions persisted for several hours after drug removal and were not formed at 4°C. Et743 treatment induced transient p53 elevation, dose-dependent cell cycle accumulation in G₂-M and in G₁- and S-phase, and inhibition of DNA synthesis. The sensitivity of camptothecin-resistant mouse leukemia P388/CPT45 cells, which fail to express detectable top1, was similar to the sensitivity of wild-type P388 cells, suggesting that top1 is not a critical target for the antiproliferative activity of Et743.

This article has been cited by other articles:

				J. Guirouilh-Barbat, C. Redon, and Y. Pommier Transcription-coupled DNA Double-Strand Breaks Are Mediated via the Nucleotide Excision Repair and the Mre11-Rad50-Nbs1 Complex Mol. Biol. Cell, September 1, 2008; 19(9): 3969 - 3981. [Abstract] [Full Text] [PDF]

				J. Fayette, I. R. Coquard, L. Alberti, D. Ranchere, H. Boyle, and J.-Y. Blay ET-743: A Novel Agent with Activity in Soft Tissue Sarcomas Oncologist, November 1, 2005; 10(10): 827 - 832. [Abstract] [Full Text] [PDF]

				N. Martinez, M. Sanchez-Beato, A. Carnero, V. Moneo, J. C. Tercero, I. Fernandez, M. Navarrete, J. Jimeno, and M. A. Piris Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients Mol. Cancer Ther., May 1, 2005; 4(5): 814 - 823. [Abstract] [Full Text] [PDF]

				A. Biroccio, C. Gabellini, S. Amodei, B. Benassi, D. Del Bufalo, R. Elli, A. Antonelli, M. D'Incalci, and G. Zupi Telomere Dysfunction Increases Cisplatin and Ecteinascidin-743 Sensitivity of Melanoma Cells Mol. Pharmacol., March 1, 2003; 63(3): 632 - 638. [Abstract] [Full Text] [PDF]

				N. Takahashi, W. Li, D. Banerjee, Y. Guan, Y. Wada-Takahashi, M. F. Brennan, T.-C. Chou, K. W. Scotto, and J. R. Bertino Sequence-dependent Synergistic Cytotoxicity of Ecteinascidin-743 and Paclitaxel in Human Breast Cancer Cell Lines in Vitro and in Vivo Cancer Res., December 1, 2002; 62(23): 6909 - 6915. [Abstract] [Full Text] [PDF]

				A. Kanzaki, Y. Takebayashi, X.-Q. Ren, H. Miyashita, S. Mori, S.-i. Akiyama, and Y. Pommier Overcoming Multidrug Drug Resistance in P-Glycoprotein/MDR1-overexpressing Cell Lines by Ecteinascidin 743 Mol. Cancer Ther., December 1, 2002; 1(14): 1327 - 1334. [Abstract] [Full Text] [PDF]

				C. Gajate, F. An, and F. Mollinedo Differential Cytostatic and Apoptotic Effects of Ecteinascidin-743 in Cancer Cells. TRANSCRIPTION-DEPENDENT CELL CYCLE ARREST AND TRANSCRIPTION-INDEPENDENT JNK AND MITOCHONDRIAL MEDIATED APOPTOSIS J. Biol. Chem., October 25, 2002; 277(44): 41580 - 41589. [Abstract] [Full Text] [PDF]

				J. M. Reid, M. J. Kuffel, S. L. Ruben, J. J. Morales, K. L. Rinehart, D. P. Squillace, and M. M. Ames Rat and Human Liver Cytochrome P-450 Isoform Metabolism of Ecteinascidin 743 Does Not Predict Gender-dependent Toxicity in Humans Clin. Cancer Res., September 1, 2002; 8(9): 2952 - 2962. [Abstract] [Full Text] [PDF]

				S. Donald, R. D. Verschoyle, R. Edwards, D. J. Judah, R. Davies, J. Riley, D. Dinsdale, L. L. Lazaro, A. G. Smith, T. W. Gant, et al. Hepatobiliary Damage and Changes in Hepatic Gene Expression Caused by the Antitumor Drug Ecteinascidin-743 (ET-743) in the Female Rat Cancer Res., August 1, 2002; 62(15): 4256 - 4262. [Abstract] [Full Text] [PDF]

				M. D'Incalci, E. Erba, G. Damia, E. Galliera, L. Carrassa, S. Marchini, R. Mantovani, G. Tognon, R. Fruscio, J. Jimeno, et al. Unique Features of the Mode of Action of ET-743 Oncologist, June 1, 2002; 7(3): 210 - 216. [Abstract] [Full Text] [PDF]

				M. A. Villalona-Calero, S. G. Eckhardt, G. Weiss, M. Hidalgo, J. H. Beijnen, C. van Kesteren, H. Rosing, E. Campbell, M. Kraynak, L. Lopez-Lazaro, et al. A Phase I and Pharmacokinetic Study of Ecteinascidin-743 on a Daily x 5 Schedule in Patients with Solid Malignancies Clin. Cancer Res., January 1, 2002; 8(1): 75 - 85. [Abstract] [Full Text] [PDF]